WRX606
Based on 1 publication(s) in Google Scholar
WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC50 = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC50 = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.65%
- CAS. Nr.: 899937-47-4
- Formel: C28H25ClN4O6
- Molecular Weight:548.97
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) WRX606
More
Biologische Aktivität
Beschreibung
In Vitro
WRX606 (1 μM) induces ternary complex formation in HEK293 cells[1].
WRX606 (100 nM-100 M, 72 h) inhibits cancer cell (HeLa and MCF-7) growth via cytotoxic effects[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa and MCF-7
-
Concentration:100 nM, 10 μM, 100 mM, 10 M, 100 M
-
Incubation Time:72 h
-
Result:Resulted in a decrease in the cell viability of both HeLa (IC50 = 3.5 nM) and MCF-7 (IC50 = 62.3 nM) cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c cancer-bearing mice with 4T1 breast cancer cells orthotopically implanted into the mammary fat pad[1]
-
Dosage:25 mg/kg/day
-
Administration:Oral gavage (p.o.) for 10 days
-
Result:Significantly suppressed tumor growth compared to the controls.
Did not promote tumor metastasis.
Had no adverse effects in kidney and liver functions.
Chemical Information
-
CAS. Nr. 899937-47-4
-
Appearance Solid
-
Molecular Weight 548.97
-
Formel C28H25ClN4O6
-
Color White to off-white
-
SMILES
O=C(CN1C(N(CCCC(NCC2=CC=C3OCOC3=C2)=O)C(C4=C1C=CC=C4)=O)=O)NC5=CC(Cl)=CC=C5
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 25 mg/mL (45.54 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Shams R, et al., In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. J Med Chem. 2022 Jan 27;65(2):1329-1341. [Content Brief]
[2]. Li, S., et al., (2023). MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation. European journal of medicinal chemistry, 260, 115781. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8216 mL | 9.1080 mL | 18.2159 mL | 45.5398 mL |
| 5 mM | 0.3643 mL | 1.8216 mL | 3.6432 mL | 9.1080 mL | |
| 10 mM | 0.1822 mL | 0.9108 mL | 1.8216 mL | 4.5540 mL | |
| 15 mM | 0.1214 mL | 0.6072 mL | 1.2144 mL | 3.0360 mL | |
| 20 mM | 0.0911 mL | 0.4554 mL | 0.9108 mL | 2.2770 mL | |
| 25 mM | 0.0729 mL | 0.3643 mL | 0.7286 mL | 1.8216 mL | |
| 30 mM | 0.0607 mL | 0.3036 mL | 0.6072 mL | 1.5180 mL | |
| 40 mM | 0.0455 mL | 0.2277 mL | 0.4554 mL | 1.1385 mL |
WRX606 Related Classifications
HY-W348485 Related Classifications
Powered by Bioz